Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Oct 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-10-20

Reporting Person: Chopas James George (VP/Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-20	Common Stock	A	882	—	Acquired	8482	Direct

Footnotes

F1: This represents a restricted stock unit that vest 50% annually over two years from grant date, subject to continued service.